Investors looking for validation of a biotech company's technology often rely on the reputation of its partners as surrogates for their own due diligence. But when the partner is a relative unknown name, a little more work is required.

Medarex Inc., which last week partnered its MDX-RA and MDX-210 antibodies with Scil Biomedicals GmbH, believes it has found a partner with European marketing muscle that will take on substantial development costs while letting MEDX